Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nanobiotix ADR Representing Ord Shs NBTX

Healthcare Biotechnology
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and... see more

Recent & Breaking News (NDAQ:NBTX)

NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets

Business Wire January 10, 2022

NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer

Business Wire January 5, 2022

Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022

Business Wire January 4, 2022

Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company's Share Capital

Business Wire December 8, 2021

NANOBIOTIX to Present at the 4th Annual Evercore ISI HealthCONx Conference

Business Wire November 17, 2021

NANOBIOTIX Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and Checkpoint Inhibitor Combination

Business Wire November 9, 2021

NANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare Conference

Business Wire November 3, 2021

NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Frail Patients With HNSCC in Phase I Expansion Evaluating Nbtxr3 as a Single Agent Activated by Radiotherapy

Business Wire October 24, 2021

NANOBIOTIX Provides Third Quarter Operational and Financial Update

Business Wire October 20, 2021

Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company's Share Capital

Business Wire October 8, 2021

NANOBIOTIX to Present First Survival Data From Priority Head and Neck Cancer Program Among Five Presentations at the 2021 Annual Meeting of the American Society for Radiation Oncology

Business Wire October 6, 2021

NANOBIOTIX Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May "Reprogram" the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect

Business Wire September 28, 2021

Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company's Share Capital as of August 31, 2021

Business Wire September 9, 2021

NANOBIOTIX Provides Business Update and Reports Financial Results for the First Half of 2021

Business Wire September 8, 2021

Nanobiotix to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Business Wire September 7, 2021

Nanobiotix Provides Second Quarter Operational and Financial Update

Business Wire July 20, 2021

NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer

Business Wire June 30, 2021

NANOBIOTIX to Host Virtual KOL Event Discussing Potential First-in-Class Radioenhancer NBTXR3 In Immunotherapy on June 11, 2021

Business Wire June 7, 2021

NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure

Business Wire June 3, 2021

NANOBIOTIX Announces the Appointment of Bart Van Rhijn as Chief Financial Officer and Member of the Executive Board to Support Global Expansion

Business Wire June 1, 2021